SPRB vs. DRRX, APRE, CASI, DARE, ENLV, JAN, THTX, FBRX, FBIO, and ACST
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include DURECT (DRRX), Aprea Therapeutics (APRE), CASI Pharmaceuticals (CASI), Daré Bioscience (DARE), Enlivex Therapeutics (ENLV), JanOne (JAN), Theratechnologies (THTX), Forte Biosciences (FBRX), Fortress Biotech (FBIO), and Acasti Pharma (ACST). These companies are all part of the "pharmaceutical preparations" industry.
DURECT (NASDAQ:DRRX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, community ranking, valuation, earnings, analyst recommendations, institutional ownership and profitability.
In the previous week, DURECT had 2 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for DURECT and 0 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 0.34 beat DURECT's score of 0.00 indicating that DURECT is being referred to more favorably in the media.
DURECT has higher earnings, but lower revenue than Spruce Biosciences. DURECT is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
DURECT received 278 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 65.83% of users gave DURECT an outperform vote while only 64.41% of users gave Spruce Biosciences an outperform vote.
28.0% of DURECT shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 4.3% of DURECT shares are owned by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
DURECT has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.5, meaning that its share price is 150% more volatile than the S&P 500.
DURECT currently has a consensus target price of $27.50, suggesting a potential upside of 2,596.08%. Spruce Biosciences has a consensus target price of $5.67, suggesting a potential upside of 570.21%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe DURECT is more favorable than Spruce Biosciences.
DURECT has a net margin of -323.16% compared to DURECT's net margin of -474.96%. DURECT's return on equity of -52.31% beat Spruce Biosciences' return on equity.
Summary
DURECT beats Spruce Biosciences on 11 of the 18 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
